Pathophysiological Roles of AMP in Hypertrophied Heart

  • Chunhua Cao (Department of Physiology, Medical School, Institute for Medical Sciences, Chonbuk National University) ;
  • Han, Jeong-Hee (Department of Physiology, Medical School, Institute for Medical Sciences, Chonbuk National University) ;
  • Kim, Sung-Zoo (Department of Physiology, Medical School, Institute for Medical Sciences, Chonbuk National University) ;
  • Cho, Kyung-Woo (Department of Physiology, Medical School, Institute for Medical Sciences, Chonbuk National University) ;
  • Kim, Suhn-Hee (Department of Physiology, Medical School, Institute for Medical Sciences, Chonbuk National University)
  • Published : 2003.06.01

Abstract

Cardiac atrium is now well-known as an endocrine organ which secretes atrial natriuretic peptide (AMP), participating in the regulation of body fluid and blood pressure. ANP is released mainly from cardiac muscle cells in response to various physiological and pathological conditions to induce atrial stretch. Ca$\^$2+/ may be one of the most important factors affecting ANP secretion even though controversy still persists. The aim of the present study is to investigate the effect of lysophosphatidylcholines (LPCs) and moxonidine on atrial hemodynamics and ANP secretion in hypertrophied atria. LPC is an endogenous phospholipid released from cell membrane during ischemia, and moxonidine is a imidazoline 1 (Il) receptor agonoist.

Keywords